Hutchison China Meditech Limited operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Hutchison China Meditech Limited with three other
miscellaneous service companies in Asia:
Syngene International Ltd
sales of 8.60 billion Indian Rupees [US$126.15 million]
Shin Nippon Biomedical Laboratories Ltd
(17.84 billion Japanese Yen [US$155.70 million]
of which 66%
was Pre-Clinical Business), and
Takara Bio Inc
based in Japan
(25.97 billion Japanese Yen [US$226.71 million]
of which 91%
was Bio support).
Hutchison China Meditech Limited reported sales of 1.12 billion Chinese Renmimbi (US$162.38 million)
December of 2015.
increase of 97.8%
versus 2014, when the company's sales were 566.54 million Chinese Renmimbi.
Sales of Consumer Products Prc saw an increase
that was more than double the company's growth rate: sales were up
1,322.0% in 2015, from
1.34 million Chinese Renmimbi to 19.04 million Chinese Renmimbi.
Hutchison China Meditech Limited also saw significant increases in sales in
Drugs Prc (up 332.9% to 663.26 million Chinese Renmimbi)
Not all segments of Hutchison China Meditech Limited experienced an increase in sales in 2015:
sales of Drug R and D fell 1.5% to 327.08 million Chinese Renmimbi.